Immunomodulation of psoriasis with a topical cyclosporin A formulation

J I Duncan, R A Wakeel, A J Winfield, Anthony Ormerod, A W Thomson

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Topical cyclosporin A (CyA; Sandimmun) in a formulation incorporating the penetration enhancers (PE) propylene glycol (18%) and azone (2%) was tested for efficacy in a double-blind, vehicle-controlled trial in 5 chronic plaque psoriatic patients. On each patient, two similar plaques were treated daily, under occlusion, for 4 weeks with either 8% (w/v) CyA, containing PE, or with vehicle comprising olive oil with PE. All sites improved significantly, but there was no significant difference between those receiving active and control preparations. Cryostat sections of biopsies performed after 4 weeks' treatment showed significant reductions in CyA compared with vehicle-treated sites in the number of cells, positive for CD3 and CD25 in the epidermis and CD25 and HLA-DR in the dermis. These results suggest that amounts of CyA adequate to affect the lymphocytic infiltrate penetrated the epidermis but that only partial suppression occurred in the dermis, as indicated by the reduction in lymphocyte activation status.
Original languageEnglish
Pages (from-to)84-87
Number of pages4
JournalActa Dermato-Venereologica
Volume73
Issue number2
Publication statusPublished - 1 Apr 1993

Fingerprint

Immunomodulation
Dermis
Psoriasis
Epidermis
Cyclosporine
Propylene Glycol
HLA-DR Antigens
Lymphocyte Activation
Cell Count
Biopsy
Therapeutics
laurocapram
Olive Oil

Keywords

  • Administration, Cutaneous
  • Adult
  • Aged
  • Antigens, CD
  • Antigens, CD3
  • Cell Adhesion Molecules
  • Chronic Disease
  • Cyclosporine
  • Double-Blind Method
  • HLA-DR Antigens
  • Humans
  • Immune Tolerance
  • Intercellular Adhesion Molecule-1
  • Keratinocytes
  • Lymphocyte Activation
  • Lymphocyte Function-Associated Antigen-1
  • Male
  • Middle Aged
  • Psoriasis
  • Receptors, Interleukin-2
  • Skin
  • Vehicles

Cite this

Duncan, J. I., Wakeel, R. A., Winfield, A. J., Ormerod, A., & Thomson, A. W. (1993). Immunomodulation of psoriasis with a topical cyclosporin A formulation. Acta Dermato-Venereologica, 73(2), 84-87.

Immunomodulation of psoriasis with a topical cyclosporin A formulation. / Duncan, J I; Wakeel, R A; Winfield, A J; Ormerod, Anthony; Thomson, A W.

In: Acta Dermato-Venereologica, Vol. 73, No. 2, 01.04.1993, p. 84-87.

Research output: Contribution to journalArticle

Duncan, JI, Wakeel, RA, Winfield, AJ, Ormerod, A & Thomson, AW 1993, 'Immunomodulation of psoriasis with a topical cyclosporin A formulation', Acta Dermato-Venereologica, vol. 73, no. 2, pp. 84-87.
Duncan JI, Wakeel RA, Winfield AJ, Ormerod A, Thomson AW. Immunomodulation of psoriasis with a topical cyclosporin A formulation. Acta Dermato-Venereologica. 1993 Apr 1;73(2):84-87.
Duncan, J I ; Wakeel, R A ; Winfield, A J ; Ormerod, Anthony ; Thomson, A W. / Immunomodulation of psoriasis with a topical cyclosporin A formulation. In: Acta Dermato-Venereologica. 1993 ; Vol. 73, No. 2. pp. 84-87.
@article{bb7f3bef695f4b5a9108b53c96c4b185,
title = "Immunomodulation of psoriasis with a topical cyclosporin A formulation",
abstract = "Topical cyclosporin A (CyA; Sandimmun) in a formulation incorporating the penetration enhancers (PE) propylene glycol (18{\%}) and azone (2{\%}) was tested for efficacy in a double-blind, vehicle-controlled trial in 5 chronic plaque psoriatic patients. On each patient, two similar plaques were treated daily, under occlusion, for 4 weeks with either 8{\%} (w/v) CyA, containing PE, or with vehicle comprising olive oil with PE. All sites improved significantly, but there was no significant difference between those receiving active and control preparations. Cryostat sections of biopsies performed after 4 weeks' treatment showed significant reductions in CyA compared with vehicle-treated sites in the number of cells, positive for CD3 and CD25 in the epidermis and CD25 and HLA-DR in the dermis. These results suggest that amounts of CyA adequate to affect the lymphocytic infiltrate penetrated the epidermis but that only partial suppression occurred in the dermis, as indicated by the reduction in lymphocyte activation status.",
keywords = "Administration, Cutaneous, Adult, Aged, Antigens, CD, Antigens, CD3, Cell Adhesion Molecules, Chronic Disease, Cyclosporine, Double-Blind Method, HLA-DR Antigens, Humans, Immune Tolerance, Intercellular Adhesion Molecule-1, Keratinocytes, Lymphocyte Activation, Lymphocyte Function-Associated Antigen-1, Male, Middle Aged, Psoriasis, Receptors, Interleukin-2, Skin, Vehicles",
author = "Duncan, {J I} and Wakeel, {R A} and Winfield, {A J} and Anthony Ormerod and Thomson, {A W}",
year = "1993",
month = "4",
day = "1",
language = "English",
volume = "73",
pages = "84--87",
journal = "Acta Dermato-Venereologica",
issn = "0001-5555",
publisher = "Society for the Publication of Acta Dermato-Venereologica",
number = "2",

}

TY - JOUR

T1 - Immunomodulation of psoriasis with a topical cyclosporin A formulation

AU - Duncan, J I

AU - Wakeel, R A

AU - Winfield, A J

AU - Ormerod, Anthony

AU - Thomson, A W

PY - 1993/4/1

Y1 - 1993/4/1

N2 - Topical cyclosporin A (CyA; Sandimmun) in a formulation incorporating the penetration enhancers (PE) propylene glycol (18%) and azone (2%) was tested for efficacy in a double-blind, vehicle-controlled trial in 5 chronic plaque psoriatic patients. On each patient, two similar plaques were treated daily, under occlusion, for 4 weeks with either 8% (w/v) CyA, containing PE, or with vehicle comprising olive oil with PE. All sites improved significantly, but there was no significant difference between those receiving active and control preparations. Cryostat sections of biopsies performed after 4 weeks' treatment showed significant reductions in CyA compared with vehicle-treated sites in the number of cells, positive for CD3 and CD25 in the epidermis and CD25 and HLA-DR in the dermis. These results suggest that amounts of CyA adequate to affect the lymphocytic infiltrate penetrated the epidermis but that only partial suppression occurred in the dermis, as indicated by the reduction in lymphocyte activation status.

AB - Topical cyclosporin A (CyA; Sandimmun) in a formulation incorporating the penetration enhancers (PE) propylene glycol (18%) and azone (2%) was tested for efficacy in a double-blind, vehicle-controlled trial in 5 chronic plaque psoriatic patients. On each patient, two similar plaques were treated daily, under occlusion, for 4 weeks with either 8% (w/v) CyA, containing PE, or with vehicle comprising olive oil with PE. All sites improved significantly, but there was no significant difference between those receiving active and control preparations. Cryostat sections of biopsies performed after 4 weeks' treatment showed significant reductions in CyA compared with vehicle-treated sites in the number of cells, positive for CD3 and CD25 in the epidermis and CD25 and HLA-DR in the dermis. These results suggest that amounts of CyA adequate to affect the lymphocytic infiltrate penetrated the epidermis but that only partial suppression occurred in the dermis, as indicated by the reduction in lymphocyte activation status.

KW - Administration, Cutaneous

KW - Adult

KW - Aged

KW - Antigens, CD

KW - Antigens, CD3

KW - Cell Adhesion Molecules

KW - Chronic Disease

KW - Cyclosporine

KW - Double-Blind Method

KW - HLA-DR Antigens

KW - Humans

KW - Immune Tolerance

KW - Intercellular Adhesion Molecule-1

KW - Keratinocytes

KW - Lymphocyte Activation

KW - Lymphocyte Function-Associated Antigen-1

KW - Male

KW - Middle Aged

KW - Psoriasis

KW - Receptors, Interleukin-2

KW - Skin

KW - Vehicles

M3 - Article

C2 - 8103272

VL - 73

SP - 84

EP - 87

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

SN - 0001-5555

IS - 2

ER -